PACES DIGEST

🔥 Landmark SGLT2 Inhibitor Trials 🔴 CV Outcome Trials (T2D) • EMPA-REG OUTCOME (2015) – Empagliflozin • CANVAS Program (2017) – Canagliflozin • DECLARE–TIMI 58 (2019) – Dapagliflozin • VERTIS-CV (2020) – Ertugliflozin 🔵 Heart Failure Trials 🫀 HFrEF • DAPA-HF (2019) – Dapagliflozin • EMPEROR-Reduced (2020) – Empagliflozin 🫀 HFpEF/HFmrEF • EMPEROR-Preserved (2021) – Empagliflozin • DELIVER (2022) – Dapagliflozin ⚡Acute/WHF • EMPA-RESPONSE-AHF Trial (2020) – Empagliflozin (2020) • SOLOIST-WHF Trial (2020) – Sotagliflozin • EMPAG-HF Trial (2022) – Empagliflozin) • EMPULSE Trial (2023) – Empagliflozin) 🔴 Acute MI • EMMY Trial (2022) • DAPA-MI Trial (2024) • EMPACT-MI Trial (2024) 🟢 Chronic Kidney Disease (CKD) Trials • CREDENCE (2019) – Canagliflozin (T2D + CKD) • DAPA-CKD (2020) – Dapagliflozin (with/without diabetes) • EMPA-KIDNEY (2023) – Empagliflozin (broader CKD population) 🟡 Special / Overlap Trial • SCORED (2021) – Sotagliflozin (T2D + CKD, CV outcomes focus)